Compare · MRK vs PHVS
MRK vs PHVS
Side-by-side comparison of Merck & Company Inc. (MRK) and Pharvaris N.V. (PHVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and PHVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $358.21B, about 173.5x PHVS ($2.06B).
- MRK has been more active in the news (16 items in the past 4 weeks vs 14 for PHVS).
- MRK has more recent analyst coverage (25 ratings vs 14 for PHVS).
- Company
- Merck & Company Inc.
- Pharvaris N.V.
- Price
- -
- -
- Market cap
- $358.21B
- $2.06B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 16
- 14
- Recent ratings
- 25
- 14
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Latest MRK
- SEC Form 8-K filed by Merck & Company Inc.
- Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
- Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
- Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
- CAPVAXIVE® Included in Ontario's Publicly Funded Adult Pneumococcal Immunization Program
Latest PHVS
- SEC Form 4 filed by Pharvaris N.V.
- Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
- Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
- Director Monges Viviane exercised 11,969 shares at a strike of $8.05 and sold $395,524 worth of shares (11,969 units at $33.05) (SEC Form 4)
- President Lu Peng exercised 45,308 shares at a strike of $2.59, increasing direct ownership by 70% to 110,261 units (SEC Form 4)
- Director Schikan Johannes Gerardus Christiaan Petrus exercised 800 shares at a strike of $20.00 and sold $28,952 worth of shares (800 units at $36.19) (SEC Form 4)
- CFO / CLO Nassif David W. sold $218,801 worth of shares (6,000 units at $36.47) and gifted 500 shares, decreasing direct ownership by 5% to 113,800 units (SEC Form 4)
- President Lu Peng exercised 100,000 shares at a strike of $2.59 and sold $3,500,000 worth of shares (100,000 units at $35.00) (SEC Form 4)
- Director Schikan Johannes Gerardus Christiaan Petrus sold $7,000,000 worth of shares (200,000 units at $35.00), decreasing direct ownership by 63% to 115,167 units (SEC Form 4)
- SEC Form 144 filed by Pharvaris N.V.